|Bid||1,622.00 x 175400|
|Ask||1,645.00 x 417900|
|Day's Range||1,626.50 - 1,659.52|
|52 Week Range||1,363.00 - 1,745.56|
|PE Ratio (TTM)||47.79|
|Dividend & Yield||1.01 (4.77%)|
|1y Target Est||N/A|
Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies. The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found the U.S. company's European unit, Merck Sharp & Dohme, had abused its dominant position through the scheme, opening it up to potential financial penalties.
Celldex Therapeutics and Agenus have promising oncology pipelines, but which is the better stock right now?
Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.